Efficacy and safety of initial combined therapy with metformin plus a dipeptidyl peptidase-4 inhibitor versus metformin monotherapy in type 2 diabetes mellitus: a systematic review and meta-analysis of phase 3 randomised controlled trials

被引：0
|
作者：
Tangney, N. [1 ]
De Buitleir, C. [1 ,2 ,3 ]
O'Brien, T. [1 ,2 ]
Liew, A. [1 ,2 ,3 ]
机构：
[1] Galway Univ Hosp, Galway, Ireland
[2] NUIG, Discipline Med, Galway, Ireland
[3] Portiuncula Univ Hosp, Galway, Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2019年 / 188卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P132
引用
收藏
页码：S248 / S248
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis
    Wu, D.
    Li, L.
    Liu, C.
    DIABETES OBESITY & METABOLISM, 2014, 16 (01): : 30 - 37
  • [2] Metformin monotherapy versus dual therapy with metformin and a dipeptidyl peptidase-IV inhibitor for treatment of type 2 diabetes mellitus: a systematic review and meta-analysis
    Tobin-Schnittger, P.
    Ong, G.
    O'Brien, T.
    Liew, A.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2016, 185 : 397 - 397
  • [3] Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors
    Alanazi, Abdulrahman S.
    SAUDI PHARMACEUTICAL JOURNAL, 2015, 23 (06) : 603 - 613
  • [4] Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis
    Foroutan, Naghmeh
    Muratov, Sergei
    Levine, Mitchell
    CLINICAL AND INVESTIGATIVE MEDICINE, 2016, 39 (02): : E48 - E62
  • [5] Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis
    Min, Se Hee
    Yoon, Jeong-Hwa
    Hahn, Seokyung
    Cho, Young Min
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (04) : 893 - 902
  • [6] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
    Charbonnel, Bernard
    Karasik, Avraham
    Liu, Ji
    Wu, Mei
    Meininger, Gary
    DIABETES CARE, 2006, 29 (12) : 2638 - 2643
  • [7] Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
    Wang, Zhiying
    Sun, Jiahui
    Han, Ruobing
    Fan, Dongzhu
    Dong, Xinyi
    Luan, Zenghui
    Xiang, Rongwu
    Zhao, Mingyi
    Yang, Jingyu
    DIABETES OBESITY & METABOLISM, 2018, 20 (01): : 113 - 120
  • [8] Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
    Nauck, M. A.
    Ellis, G. C.
    Fleck, P. R.
    Wilson, C. A.
    Mekki, Q.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (01) : 46 - 55
  • [9] Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis
    Kim, Yeong Gi
    Min, Se Hee
    Hahn, Seokyung
    Oh, Tae Jung
    Park, Kyong Soo
    Cho, Young Min
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 116 : 86 - 95
  • [10] Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients
    Wang, Fei
    He, Yuan
    Zhang, Rong
    Zeng, Qiang
    Zhao, Xiaolan
    MEDICINE, 2017, 96 (36)
12345